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Abstract
In developing an oral bait BCG vaccine against tuberculosis in badgers we wanted to under-
stand the conditions of the gastrointestinal tract and their impact on vaccine viability. Condi-
tions mimicking stomach and small-intestine caused substantial reduction in BCG viability.
We performed in vivo experiments using a telemetric pH monitoring system and used the
data to parameterise a dynamic in vitro system (TIM-1) of the stomach and small intestine.
Some BCG died in the stomach compartment and through the duodenum and jejunum com-
partments. BCG survival in the stomach was greatest when bait was absent but by the time
BCG reached the jejunum, BCG viability was not significantly affected by the presence of
bait. Our data suggest that from a starting quantity of 2.85 ± 0.45 x 108 colony-forming units
of BCG around 2 log10 may be killed before delivery to the intestinal lymphoid tissue. There
are economic arguments for reducing the dose of BCG to vaccinate badgers orally. Our find-
ings imply this could be achieved if we can protect BCG from the harsh environment of the
stomach and duodenum. TIM-1 is a valuable, non-animal model with which to evaluate and
optimise formulations to maximise BCG survival in the gastrointestinal tract.
Introduction
European badgers (Meles meles) are hosts of Mycobacterium bovis and represent self-sustaining
wildlife reservoirs of potential tuberculosis transmission to farmed cattle and other animal spe-
cies [1]. Tuberculosis (TB) infection in livestock has a significant economic impact on farming
and UK taxpayers. Since badgers are protected animals under UK law, vaccination is one pos-
sible approach to managing the disease in wild badger populations and forms part of the TB
eradication strategy for England [2] and Wales [3].
PLOS ONE | https://doi.org/10.1371/journal.pone.0214859 April 19, 2019 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Williams GA, Koenen ME, Havenaar R,
Wheeler P, Gowtage S, Lesellier S, et al. (2019)
Survival of Mycobacterium bovis BCG oral vaccine
during transit through a dynamic in vitro model
simulating the upper gastrointestinal tract of
badgers. PLoS ONE 14(4): e0214859. https://doi.
org/10.1371/journal.pone.0214859
Editor: Riccardo Manganelli, University of Padova,
Medical School, ITALY
Received: October 1, 2018
Accepted: March 22, 2019
Published: April 19, 2019
Copyright: © 2019 Williams et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript, Supporting Information
files, and on Figshare (https://doi.org/10.6084/m9.
figshare.7925288.v1; https://doi.org/10.6084/m9.
figshare.7925333.v1).
Funding: GAW, PW, SG, SL and MAC were
supported by grant SE3246 awarded by the UK
government Department for Environment, Food
and Rural Affairs (Defra) - https://www.gov.uk/
government/organisations/department-for-
Parenterally delivered Bacillus Calmette-Gue´rin (BCG) vaccine reduces the severity and pro-
gression of experimentally induced M. bovis infection in captive badgers and also exerts a protec-
tive effect against the disease in wild badgers [4–7]. The Animal and Plant Health Agency
(APHA) holds the UK Limited Marketing Authorisation for BadgerBCG, a vaccine delivered by
intramuscular injection to badgers to reduce lesions caused by M. bovis infection. A more practi-
cal and cost-effective strategy for vaccination of wild animals is likely to be self-administered oral
BCG vaccine in a bait deployed in the field. Oral BCG vaccination has been shown to provide
protection in a number of wildlife species including badgers [8–14]. For oral uptake by badgers,
the vaccine will be prepared in a food bait matrix with high palatability for badgers [15, 16].
The precise site(s) and detailed mechanism(s) of BCG uptake in vivo following ingestion
are unclear. BCG can be phagocytosed by Peyer’s patch microfold-cells (M-cells) of the small
intestine before transmission to macrophages present in underlying epithelial tissue [17]. It is
therefore reasonable to assume that the badger small intestine may well serve as an important
site of BCG uptake from the lumen of the small intestine during transit of the oral vaccine.
Ingested BCG must be capable of surviving the physicochemical stresses of gastric and intesti-
nal digestive conditions in the gut such that the number of live bacteria arriving at M-cells
remains high enough to elicit protective immunity [18, 19]. The fact that very few BCG cells
were recovered from the faeces of badgers given high doses of live BCG orally [20] suggests
that the death of orally administered BCG in the gut could be limiting maximal efficacy of the
vaccine. This is supported by the observation that BCG Moreau was reduced in survival by
40% and by 65% following two hour incubations in artificial gastric or duodenal solutions,
respectively [21] and by our similar findings for BCG Danish in simulated gastric and intesti-
nal fluids (this paper).
We sought to gain a deeper understanding of the specific conditions of the badger gastroin-
testinal tract (GIT), the impact this environment has on BCG viability, and whether viability
was influenced by inclusion of the vaccine in a candidate bait delivery system. The Bravo pH
Monitoring System (Medtronic Ltd) was developed originally for wireless sensing of gastric
pH in humans [22] but has since been used to measure gastric pH and residence time in dogs
[23, 24]. We conducted remote-sensing experiments using the Bravo System to generate data
on the pH and retention times in the different compartments of the badger GIT.
As studying BCG survival in vivo raises both practical and ethical concerns, we instead evalu-
ated the survival of BCG in the context of different bait formulations using the TNO TIM-1 gas-
trointestinal model. The TIM-1 system simulates in high degree the successive dynamic
processes in the stomach and small intestine [25] and has been used previously to determine bac-
terial survival during gastrointestinal transit simulating human GIT conditions [26–28] and
using validated (fed-state) canine digestion parameters [29]. Mixing of contents within each
compartment is a key feature of the system and is achieved by alternating the pressure on flexible
walls. All contractile movements and the resulting mixing and pressure profiles are accurately
controlled and synchronised. To more accurately model badger digestion we refined the canine
model parameters to incorporate the in vivo pH and gastrointestinal transit time data obtained
from captive badgers using the Bravo system. We report the use of the TIM-1 system to compare
the survival rate of BCG bacteria without and with different baits after passage through the stom-
ach and the proximal and middle parts of the small intestine; the duodenum and jejunum.
Materials and methods
All animal work was reviewed and approved by the Animal Welfare and Ethical Review Board
of the Animal and Plant Health Agency and was conducted under Home Office A(SP)A
licence PPL 70/5965.
BCG vaccine survival through an in vitro gut model
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Test products
The test product was BCG Danish 1331 strain suspended in 1.5% (w/v) monosodium gluta-
mate (MSG) solution (supplied by the Staten Serum Institute, Copenhagen, Denmark). This
product was tested without bait or with three different bait formulations: PT (Pest-Tech bait
[15]); HPO-PT (Hardened Peanut Oil-Pest-Tech bait); CB-PT (Cocoa Butter-Pest-Tech bait).
HPO (CAS number 68425-36-5) was sourced from Sigma-Aldrich (product code 93967) and
CB (CAS number 8002-31-1) was sourced from Parchem, New Rochelle, NY.
Simulated gastric and intestinal fluids
The composition of simulated gastric and intestinal fluids are shown in S1 and S2 Tables,
respectively and were derived following consultation with Dr Alex German (expert in canine
gastro-physiology, University of Liverpool) and Prof Yvonne Perrie (expert in pharmacology,
University of Strathclyde). Unpublished measurements obtained by us from badgers post mor-
tem indicated the typical volume of a badger stomach is approximately 500 ml. Therefore, this
volume of solution was used in the in vitro tests. To examine the specific action of pepsin on
BCG, a basic gastric fluid was made from a solution of pepsin (0.32%, w/v) and the pH
adjusted to 2.5 using hydrochloric acid. To examine the effect of bile on BCG, ox bile (Sigma-
Aldrich, product code 70168) was used as a 10% solution to represent the physiological con-
centration of fresh bile in the proximal small intestine. As the pH of the ox bile solution was
7.5, a control solution of KH2PO4 was included in this experiment to match the pH, as the pH
of the MSG solution containing BCG is 6.8.
Bravo pH monitoring system
The Bravo pH Monitoring System (Medtronic, Minneapolis, MN) consists of a capsule
(26×6×6.3 mm), which is placed in the GIT using a catheter delivery system from where it
measures the pH of its environment; transmitting the data to a remote recording device [30].
Proof of principle was first demonstrated with the system by placing the capsule in the stomach
of a dead lamb (approx. 30 kg) and confirmed to be transmitting to the recording device. The
lamb (double-bagged) was taken to the badger holding facility and placed in various locations
around the compound, including within the wooden setts used by the badgers (with badgers
excluded). An optimal location for the recording device was identified that allowed the trans-
mitted pH data to be recorded at all positions within an enclosed area of the facility. Badgers
have previously been confined to this enclosed area for several weeks without problem, indi-
cating the system could be employed to record data directly from the GIT of live badgers in
the facility.
Following Home Office approval (licence, PPL 70/5965) the work progressed to studies in
captive badgers. Before use, each capsule was calibrated against a Mettler Toledo benchtop pH
meter (Fisher Scientific) in standardised buffer solutions between pH 2 and pH 10, achieving a
Pearson correlation coefficient of greater than 0.98. Capsules were placed in badgers whilst
under anaesthesia, deep in the oesophagus by intubation (insertion depth = 30-35cm) using
the sterile applicator supplied with the capsule. After a capsule was positioned, each badger
was returned to a 42 m2 enclosure for recovery and was free to feed and interact normally with
other captive badgers. The receiver was hung in the middle of the room out of reach of the
badgers within reception range (at least 5 m) from the capsule and data collected for up to 48
h. In all cases, the capsule was recovered from faeces deposited in the enclosure. Data were
recovered from the receiver using a PC and visualised using the manufacturer’s software.
BCG vaccine survival through an in vitro gut model
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Test system: Dynamic gastrointestinal system (TIM-1)
Experiments were performed in the TNO dynamic, multi-compartmental system of the stom-
ach and small intestine (TIM-1) as schematically presented in S1 Fig. This system simulates
very closely the successive dynamic conditions in the stomach and small-intestinal tract, such
as body temperature, the pH curve, concentrations of electrolytes, and the activity of enzymes
in the stomach and small intestine, the concentrations of bile salts in the different parts of the
gut, and the kinetics of transit of the chyme through the stomach and small intestine, and the
absorption of low molecular weight molecules and water. For the experiments described in
this paper, the sampling bottle was placed under peristaltic valve F instead of H (S1 Fig), in
order to sample bacteria entering the ileum.
The experiments in TIM-1 were performed under the average physiological conditions of
the stomach and small intestine as described for dogs in the fed state (light meal) [29] with
adaptations according to data from three badgers which were obtained by us using the Med-
tronic Bravo pH Monitoring System. Data for the dynamics of gastric emptying and intestinal
transit times, and the gastric and the intestinal pH values were used to set the parameters for
TIM-1 (Fig 1).
The gastric contents passed the pyloric valve into the duodenal compartment according to
the computer controlled gastric emptying, an exponential equation defining a t½ for the half
time of delivery and ß for the shape of the curve [31]. In this study t½ = 70 min and ß = 1 were
used. As such, 99% of the stomach contents had passed into the duodenal compartment by 8
hours. In the duodenal compartment the gastric content was neutralised to pH 6.3 ± 0.2, and
bile and pancreatin were secreted. The content of the duodenum (passage time ± 10 min) was
gradually delivered into the jejunum (pH 7.2 ± 0.2) compartment. After a jejunal passage time
of approximately 90 min, the contents was emptied in a beaker on ice containing dilution
buffer (physiological salt with 0.05% Tween) in order to immediately dilute the enzymes and
bile. In each compartment the physiological concentrations of bile salts, pancreatic enzymes
and electrolytes were simulated in combination with the average physiological passage of the
chyme through the small intestine. The digested and soluble (low-molecular weight) com-
pounds were removed continuously from the jejunum compartment of the model via a special
dialysis membrane system.
For each experiment the secretion products (e.g. salivary and gastric juice with enzymes,
electrolytes, dialysis liquids, bile and pancreatic juice) were freshly prepared, the pH electrodes
calibrated and the dialysis membrane (hollow fibre units) replaced.
Cleaning and decontamination of the TIM-1 system
The cleaning procedure of the TIM-1 system was adapted to the need for plating bacteria. As
sterilising the system is not possible, the system was cleaned after each run, first with water
and thereafter filled with a soap solutions (0.1 M NaOH in 2% RBS solution) and left in the
cleaning solution overnight.
The day before an experimental run, the glassware of the system was clicked off the machine
and put in the sink. The compartments were cleaned with water and after that put in a bleach
solution for at least 30 minutes. After this the units were rinsed with water, then with 0.5 M HCl,
then with water and finally with 70% ethanol. The units were dried and kept dry and empty until
use. Just before use all electrodes, sensors and caps were rinsed with 70% ethanol and dried.
Set up of the experiments
Two separate studies were performed. In Study 1, four replicate experiments were performed
over two days and included the evaluation of BCG, BCG plus HPO-PT bait and BCG plus
BCG vaccine survival through an in vitro gut model
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CB-PT bait. In Study 2, a further four replicate experiments were run over four days and
included the evaluation of BCG, BCG plus HPO-PT bait and BCG plus PT bait. In Studies 1
and 2, BCG was recovered in effluent from the jejunum. In Study 2, BCG was also recovered
in effluent directly from the stomach via the pyloric sphincter (S1B Fig).
Baits were taken out of the refrigerator the night before the TIM experiments to warm to
room temperature (approx. 21˚C). The baits were cut into four parts, then squeezed through a
strong garlic crusher in order to simulate the chewing by badgers. The artificial saliva and
water were put in a water bath until the temperature was between 42 and 45˚C. The ‘chewed’
Fig 1. Traces of pH versus time obtained from three different live badgers using the Medtronic Bravo pH Monitoring System. (A) Capsule moves into
stomach, pH declines. (B) Capsule moves from stomach into small bowel, pH rises sharply. Capsule in stomach between points A and B.
https://doi.org/10.1371/journal.pone.0214859.g001
BCG vaccine survival through an in vitro gut model
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bait was added, the mixture stirred and then introduced into the stomach of the TIM-1 system
via a funnel. When the temperature in the stomach decreased to 37˚C, 400 μl of BCG suspen-
sion was introduced into the stomach compartment. For experiments without bait matrix, it
was replaced with 30 g of citrate buffer (0.01 M concentration in the stomach content). Each of
the three vaccine preparations was tested in at least duplicate. The total intake in the gastric
compartment of the system was 300 g in all runs.
Sampling and sample treatment
Before the TIM experiments, per test day two samples of the test product were taken and ana-
lysed for the number of viable BCG ml-1, in order to determine the CFU’s in the intake for
each TIM-1 run retrospectively. During the TIM run, the gastric effluent (Study 2) and the
jejunum effluent (Studies 1 and 2) were collected in one hour aliquots into sampling bottles
with 100 ml of dilution buffer. In this way the sample was diluted in order to minimize the
effect of bile and pH in the sampling bottle on survival of BCG after passage through the TIM
system. In Study 1 the dilution buffer was phosphate buffered saline with 0.05% Tween on ice.
In Study 2 the dilution buffer was Sauton medium with 0.05% Tween. Samples were collected
at room temperature to limit the opportunities for fat to congeal in the sample. Every 60 min
the collected volume was measured and sampled. The residues in the TIM system, the lumen
present in the gastric compartment and from the combined duodenal and jejunum compart-
ments after ending the TIM experiment, were collected for analysis.
Microbiological analyses
Samples were diluted in Sauton-Tween and plated in duplicate on Modified 7H11 agar plates
in order to determine the number of CFU of BCG. The plates were closed with tape around
the edge and incubated in sealed bags for 28 days at 37˚C before counting the number of colo-
nies on each plate. For TIM-1 experiments, the survival rate of the BCG bacteria after passage
through the stomach, duodenum and jejunum was determined in at least duplicate for each
run, making adjustment for the volume of the effluent in each case.
Data calculation and statistics
After incubations of the plates, the BCG colonies were identified morphologically and counted
in duplicate. Differences between mean counts were evaluated by Student t-test or 2-way
ANOVA using GraphPad Prism version 7.03 for Windows, GraphPad Software, La Jolla Cali-
fornia USA, www.graphpad.com.
Results
Initially, we performed simple in vitro experiments using different fluids designed to mimic
the low pH and enzymatic activity of the stomach and duodenum. We wanted to ascertain
whether these conditions would cause a significant reduction in BCG viability and conse-
quently could have a detrimental effect on the protective efficacy of an oral BCG vaccine. Fig 2
shows the results of these experiments. Exposure of BCG Danish to pH 2.5 caused significant
reduction in BCG viability within 15 min (p< 0.05, t test), reaching a maximum after about
120 min. This was not increased by the inclusion of pepsin. A similar reduction in viability was
seen on incubation of BCG with ox bile, where a reduction in viability of 80% occurred after
100 min of incubation, despite BCG originally being derived from virulent M. bovis using
medium containing ox bile [32]. Reductions in BCG viability were even greater (>90%) when
more complex solutions designed to simulate gastric or intestinal fluids were used.
BCG vaccine survival through an in vitro gut model
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In order to gain more accurate information for the conditions which BCG vaccine may face
in the GIT of badgers, we performed in vivo remote-sensing experiments on three different
badgers using a Bravo pH Monitoring System (Medtronic Ltd); a telemetric capsular system
that transmits sensed pH readings in real-time. Fig 1 shows the traces obtained with the Bravo
device. The capsule was placed in the oesophagus of badgers under anaesthesia. After recovery
the badger was released into its enclosure and observed using CCTV cameras. The demarca-
tions between entry into and exit from the stomach were easy to identify on the basis of rapid
reduction and increase in pH, respectively. Readings of pH from the capsule varied between
animals as might be expected. In general, pH reached a low of 2 in the stomach and a high of 8
in the duodenum. The data across the three badgers were: pH7 within the oesophagus; reduc-
tion of pH from 7 to 2 within the stomach over a mean period of 60 min (range 10 to 105);
mean gastric retention time of 480 min (range 270 to 720); increase of pH from 2 to 8 over
Fig 2. The impact of pH, pepsin, Ox bile, SGF and SIF on the viability of BCG Danish. Data are expressed as percentage survival of BCG from the original
starting inoculum. Data are expressed as the mean values derived from quadruplicate samples and bars indicate the standard error around the mean. The data
used to generate this figure are provided in S1 Dataset.
https://doi.org/10.1371/journal.pone.0214859.g002
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mean of 75 min (range 15 to 120) on passage from stomach into duodenum. We were unable
to determine the total retention time in the intestine but it was in excess of ten hours.
We have developed and evaluated a number of different bait delivery systems and found
that bait, in-part comprised of peanut butter, cereal, and sugars, is palatable to badgers and
compatible with long-term storage of viable BCG, especially when the vaccine is enrobed
within a lipid carrier within bait [15, 16]. The physicochemical properties of the bait and vac-
cine carrier components of an oral vaccine may help to overcome the problem of BCG inacti-
vation within the GIT; for example the presence of lipid in vaccine formulations may help to
protect BCG against the bactericidal effects of gastric secretions and enhance its uptake
through the intestinal wall [33]. We evaluated the survival of BCG in the context of different
bait formulations using the TNO TIM-1 gastrointestinal system. To more accurately model
badger digestion we attempted to refine the canine model parameters to incorporate the in
vivo pH data obtained from captive badgers and to approximate the gastric retention time. In
reality it proved difficult to replicate the conditions of the badger exactly since there was con-
siderable variation between animals (Fig 1). An average gastric retention time of 480 min was
modelled successfully by the formula y = a2-t/70, such that 99% of the gastric content was pre-
dicted to have passed into the duodenum by eight hours. The dynamics of gastric pH was
harder to model and in practice it took the model three hours to reach pH2 (Fig 3); slower
than observed in vivo (Fig 1).
A total of eight TIM-1 experiments were performed over six days on two separate occasions
as part of two independent studies. The number of viable bacteria in the BCG suspension was
determined for each experiment in duplicate and ranged from 4.4 x 108 CFU ml-1 to 9.7 x 108
CFU ml-1. The variation in CFU of BCG between the days of each study was less than between
the studies, therefore we used the average number of CFU across the days to calculate the
Fig 3. The average physiological gastric emptying curve (blue line), ileum effluent curve (grey line) and gastric pH
curve (red dotted line) for badgers after the intake of a light meal as used in the TIM-1 experiments.
https://doi.org/10.1371/journal.pone.0214859.g003
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intake CFU for each study: 5.9 x 108 CFU ml-1 (SD = 1.0 x 108 CFU ml-1); and 8.2 x 108 CFU
ml-1 (SD = 3.6 x 108 CFU ml-1), respectively. As 400 μl was introduced into the TIM-stomach,
the average intake of BCG for Study 1 was 2.4 x 108 CFU and 3.3 x 108 CFU for Study 2.
Table 1 presents the net survival of BCG after passage through the TIM stomach alone (fol-
lowing the gastric emptying for three hours) or after passage through the stomach, duodenum
and jejunum compartments (following the gastric and small-intestinal passage for five hours)
for all formulations tested. The log10 reduction in survival for BCG in HPO-PT bait (2.3) or
without bait (1.9) was identical between the two independent studies, demonstrating the high
reproducibility of the model. Losses to BCG survival were incurred both in the stomach com-
partment and subsequently through the duodenum and jejunum compartments (Table 1 and
Fig 4). According to 2-way ANOVA of the data from both studies, for each formulation there
was a significant reduction in BCG survival following passage through the stomach, duode-
num and jejunum. The second study allowed us to determine that passage through the stom-
ach made the greatest contribution to this reduction. By 2-way ANOVA, for each formulation,
significantly less BCG was recovered after passage through the stomach, but the difference
between BCG recovered from the stomach and the quantity of BCG recovered from the jeju-
num was not significant.
As passage through the stomach made the greatest contribution to a reduction in BCG via-
bility, we specifically assessed the survival of BCG in three different formulations in the stom-
ach compartment over a period of three hours with BCG survival in the stomach effluent
assessed after each hour (Fig 5A). Although the small sample sizes prevent robust statistical
assessment, when expressed as a cumulative percentage of the intake, the amount of BCG
recovered from the stomach appeared to be lower for BCG with PT bait compared with
HPO-PT bait or when bait wasn’t present, consistent with the data shown in Fig 4. In both
studies, we assessed BCG survival from the stomach through to the jejunum (Fig 5B). Most of
the surviving BCG bacteria left the jejunum compartment during the first hour. In the second
hour a smaller percentage of living BCG left the jejunum compartment. Only for the BCG
without bait did the sample of the third hour contain additional living BCG bacteria. Recovery
of BCG from the stomach was significantly greater when no bait was present (Fig 4B), but by
the time of delivery to the jejunum there was no significant difference between the formula-
tions in either study (2-way ANOVA). The difference seen in the stomach compartment could
be the consequence of differences in the ability of the different formulations to buffer against
Table 1. Overview of the CFU of BCG Danish vaccine in the intake and the amount of CFU surviving passage through the stomach, duodenum and jejunum aver-
aged across four experiments in TIM-1 simulating badgers GI conditions.
Intake formulation Average intake CFU Average surviving CFU Log10 reduction in survival
Study 1: Stomach -> jejunum (5 hrs)
BCG-HPO-PT 2.4 x 108 CFU 1.2 x 106 CFU 2.3
BCG-CB-PT 2.4 x 108 CFU 4.3 x 105 CFU 2.7
BCG-no bait 2.4 x 108 CFU 2.8 x 106 CFU 1.9
Study 2: Stomach only (3 hrs):
BCG-HPO-PT 3.3 x 108 CFU 1.6 x 107 CFU 1.3
BCG-PT 3.3 x 108 CFU 7.6 x 106 CFU 1.6
BCG-no bait 3.3 x 108 CFU 4.3 x 107 CFU 0.9
Study 2: Stomach -> jejunum (5 hrs):
BCG-HPO-PT 3.3 x 108 CFU 1.5 x 106 CFU 2.3
BCG-PT 3.3 x 108 CFU 1.2 x 106 CFU 2.4
BCG-no bait 3.3 x 108 CFU 4.5 x 106 CFU 1.9
https://doi.org/10.1371/journal.pone.0214859.t001
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acidity. In all experiments where it was examined, gastric pH reduced slowly during the first
hour of the meal, more rapidly during the second hour, and then reduced more slowly for the
final third hour (Fig 6). This profile was slower than the gastric pH profile observed in vivo
using the Bravo device (Fig 1). There was no obvious difference in the pH profile between for-
mulations, although during the second hour there was the suggestion that BCG without bait
might buffer slightly better in a couple of the experimental runs.
Focusing on the stomach to jejunum, survival of BCG also appeared greater when bait was
absent (Fig 4A and 4B). However, these differences were not statistically significant. There was
also no significant difference in BCG survival in HPO-PT bait compared with CB-PT bait (Fig
4A) or PT bait (Fig 4B). CB-PT and PT were not compared within the same study.
The HPO-PT and CB-PT baits (two pieces were used for every TIM experiment) were 50–
60% lipid by weight. Especially the HPO in bait had to be melted before it could be adminis-
tered into the TIM stomach. During the runs with this bait the fat in the stomach was emptied
into the duodenum compartment, but after the run had been completed it became clear that
fat had accumulated at the side of the stomach and had become more solid again. The fat was
removed from the stomach as much as possible after the run, and the residues were also plated
to see if living BCG was present there. The quantity of BCG remaining in the stomach three
hours after feeding with BCG-HPO-PT ranged from 4.1 x 102 to 3.9 x 103 CFU across both
studies. The bait containing CB melted easier because of the lower melting point of the fat.
Therefore less fat was expected to be left behind in the stomach compartment, but in one of
the runs quite some fat accumulated right under the pyloric sphincter just above the duode-
num compartment. This fat was removed after the run and added to the residue which was
plated after the run. No BCG was recovered from this residue. Similarly, stomach residue after
consumption of BCG with PT bait contained no viable bacteria. The highest numbers of living
BCG were found in the stomach residues three hours after feeding without bait across both
studies (2.2 x 104 to 1.5 x 105 CFU). However, by five hours no BCG was recovered from the
Fig 4. Recovery of BCG from the TIM-1 system (mean CFU plus standard error shown). BCG was recovered from three separate experiments. (A) Results from Study 1
comparing recovery from the jejunum after five hours of passage from the stomach through the duodenum to the jejunum (white bars, n = 2). (B) Results from Study 2
comparing recovery from the stomach after three hours (grey bars, n = 3), or from the jejunum after five hours of passage from the stomach through the duodenum to the
jejunum (white bars, n = 3). In both cases, the black bars represent the input quantity of BCG ‘fed’ to the TIM-1 system (n = 2). BCG was introduced in three different bait
formulations (HPO-PT, CB-PT, PT) or without bait. Horizontal lines indicate means that are significantly different from one another (p < 0.05). The data used to generate
this figure are provided in S2 and S3 Datasets.
https://doi.org/10.1371/journal.pone.0214859.g004
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stomach residues in seven of eight experiments. The exception was the recovery of 150 CFU
BCG after five hours in the stomach without bait. Survival of BCG in the residues of the small
intestine varied between formulations and between experiments and ranged from 2.2 x 103 to
1.5 x 104 CFU across both studies; the highest counts again being obtained where there was no
bait.
Discussion
We first performed simple in vitro experiments to ascertain whether simulated GIT conditions
would cause a significant reduction in BCG viability and consequently could have a detrimen-
tal effect on the protective efficacy of an oral BCG vaccine. We found that the majority of BCG
Fig 5. Mean cumulative number of BCG in the stomach effluent (A) and jejunum effluent (B) as percentage of the
intake for Study 2, n = 3, mean ± stdev for BCG-HPO-PT (triangles), n = 3, mean ± stdev for BCG-PT (squares) and
n = 2, mean ± range for BCG without bait (circles).
https://doi.org/10.1371/journal.pone.0214859.g005
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was killed following incubation with solutions intended to mimic the conditions of the stom-
ach and intestine (simulated gastric and intestinal fluids, respectively). However, as these con-
ditions were derived from experience with humans and dogs, we conducted remote-sensing
experiments using a Bravo pH Monitoring System (Medtronic Ltd) to obtain more accurate
physiological GIT data for the European badger. These experiments revealed that the gastric
pH of captive badgers was around 2.0 for approximately 180 min in two badgers but only for
about 40 min in another badger, where the pH rose to 6 and then fell again. Total gastric reten-
tion time was on average 480 min, but with a wide range (270–720 min). The pH of the small-
intestinal tract was gradually increasing from 6.0 and 8.0 during transit through the duode-
num, jejunum and ileum, with potentially long retention times (>10 hrs). These results are
similar to the data obtained from Beagle dogs using the Bravo System [23, 24]. The gastric pH
of the badger was at the higher end of the range found for fed or fasted Beagles and the gastric
retention time was between that of fasted and fed dogs; being 250 min and 679 min, respec-
tively. The pH and retention time of the canine intestinal tract was not the focus of study in
the paper of Sagawa et al., but can be derived from figures therein [24]: pH of between 7 and 9;
total (stomach + intestines) retention time up to 20 h. These data are very similar to those
derived by us from badgers. We do not know the impact of general anaesthesia on gastric
motility in the badger. We use a combination of 10 mg/kg of ketamine, 100 μg/kg of medeto-
midine and 100 μg/kg of butorphanol for anaesthesia. In a study with dogs, injection of up to
30mg/kg of ketamine did not significantly affect gastric emptying nor GIT motility [34].
We used the Bravo badger data to parameterise the TIM-1 system so we could make repro-
ducible assessment of the viability of BCG vaccine as it passed through the stomach and small
intestine sections of the model and what influence bait (type and presence) had on BCG sur-
vival. The precise conditions of the badger gut could not be replicated in terms of enzymatic
secretions. Instead, we used the reagents typical of the canine configuration of the TIM-1 sys-
tem [29] on the basis that the natural diet of dogs and badgers is not dissimilar; both being evo-
lutionary omnivores. Microbial contamination of the model, after as much disinfection as
possible, was not a problem and BCG bacteria could be recovered from the samples.
The gastric environment was most detrimental to BCG survival. As BCG is unable to main-
tain intracellular pH homeostasis under conditions of particularly low pH [35], the acidic
Fig 6. pH in the stomach compartment of the TIM-1 system during all runs. BCG-HPO-PT (six shades of red and
orange), BCG-PT (six shades of blue) and BCG without bait (2 green and 3 grey shades).
https://doi.org/10.1371/journal.pone.0214859.g006
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conditions of the stomach are the most plausible explanation for our findings. However, the
finding that survival was reduced in the presence of bait was surprising and runs contrary to
previous data that suggested that the ingestion of live BCG vaccine with lipid might protect
against inactivation in the stomach [36], although different a different composition of lipid
was used in that study. The detrimental impact HPO-PT and PT baits had on BCG survival in
the stomach was not related to pH as there was no obvious impact of bait present at the same
time as BCG on the pH kinetics in the stomach. Although our data indicate that BCG without
bait might buffer slightly better in a couple of experiments, the differences were small and we
consider unlikely to account for the better survival of BCG when not in bait. One possible
explanation for our findings is that free fatty acids released by digestion within the stomach of
TIM-1 might have had an antimicrobial effect, especially longer-chain fatty acids (C12 and
above) that have been shown to be toxic to BCG [37]. Coconut oil is rich in C12 and C14 fatty
acids, whilst peanut oil is richer in C18 fatty acids, in particular [38]. However, other lipid
matrices used to suspend BCG for oral vaccination have proved successful, despite over 78% of
the composition of one of those matrices comprising lipids of C12-18 chain length [36]. A
refinement in further studies would be to mix the BCG suspension with the ‘chewed’ bait
before introducing into the stomach compartment. This difference might influence the release
and survival of the BCG bacteria during GI transit and give different results.
Further reduction in BCG survival was encountered in the intestinal region of TIM-1 but
not to the same extent as the stomach. Previous in vitro work has indicated a role for both gas-
tric and duodenal fluids in causing significant BCG death [21], something we also observed in
this study. As there is a very large Peyer’s Patch (lymphoid tissue responsible for uptake and
presentation of BCG from the gut) about 33cm long at the distal end of the small intestine of
badgers [39], the extent of survival of BCG in the jejunal effluent is the most important read-
out from the TIM-1 badger model. The log10 reduction in BCG survival from ingestion to exit
from the jejunum varied from 1.9 to 2.7 and was not significantly influenced by the presence
or absence of bait, nor the type of bait used (i.e. the proportion and type of fat present). This
could have important implications for the development of a cost-effective oral vaccine for bad-
gers. We do not currently know the minimum efficacious dose of oral BCG for use in badgers,
but published studies and unpublished studies by us suggest it may lie between 5 x 107 and 108
CFU. Our data suggest that around 2 logs of ingested BCG could be killed before delivery to
the gastric-associated lymphoid tissue. As we currently estimate that BCG is the larger propor-
tion of the cost of the vaccine bait (the bait components used in this study are relatively cheap),
there are economic incentives for trying to reduce the effective dose of BCG needed to vacci-
nate badgers. Our findings imply this could be achieved if we were better able to protect BCG
from the harsh environment of the stomach and duodenum.
A limitation of the experimental set up was the propensity for fats contained in the baits,
HPO especially, to solidify and adhere to internal surfaces of the TIM-1 system. The presence
of fatty deposits within the samples will also have reduced our efficiency in recovering BCG,
especially if the naturally hydrophobic bacteria have a propensity to partition with the lipid.
Retention of BCG in residues attached to internal surfaces of the TIM-1 system during our
experiments will increase the apparent reduction in BCG survival, however, the number of
bacteria retained in the residues of the stomach and intestinal compartments only represented
a range from 0.7% (BCG-HPO-PT) to 6% (BCG-no bait) of the total CFU recovered from the
system after five hours so have little overall impact on our findings. Furthermore, the high
reproducibility between the two studies, for BCG with HPO-PT and BCG without bait, also
suggests these practical limitations did not hamper us from achieving consistent and meaning-
ful results.
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Given that uptake of BCG from the intestine appears to be relatively inefficient [21], efforts
to improve the survival of BCG within the GIT could result in formulations that are effective at
lower doses. The observation that BCG given orally can be recovered from the cervical lymph
nodes of mice, guinea pigs and humans [40–42] implies that the oropharynx is an additional
portal of entry for BCG to the host mucosal-associated lymphoid tissue. Given the relative inef-
ficiency of oral BCG vaccination that relies upon uptake from the intestine, more effort to
understand the uptake of BCG from the oropharyngeal region could prove fruitful. Our studies
are timely, given the renewed interest in the oral delivery of BCG to humans [43]. We conclude
that the TIM-1 system provides a valuable, non-animal model with which to evaluate and opti-
mise formulations to maximise BCG survival in the GIT.
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